Ernest Nadal

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

Mariano Provencio, Ernest Nadal, Amelia Insa et al. · The Lancet Oncology · 2020 · 788 citations

Medicine, Immune Checkpoint Inhibitor, Cancer Treatment +4

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 594 citations · Full text

Medicine, Pathology, Immune Checkpoint Inhibitor +5

Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer

Mariano Provencio, Ernest Nadal, J.L. González-Larriba et al. · New England Journal of Medicine · 2023 · 397 citations · Full text

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)

Mariano Provencio, Roberto Serna‐Blasco, Ernest Nadal et al. · Journal of Clinical Oncology · 2022 · 322 citations · Full text

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo

Sara Mainardi, Antonio Mulero‐Sánchez, Anirudh Prahallad et al. · Nature Medicine · 2018 · 312 citations · Full text

Medicine, Cancer Cell Biology, Bronchial Neoplasm +9